gemfibrozil has been researched along with Kidney Diseases in 13 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nephrotoxicity is a significant side effect of doxorubicin (DXN) treatment." | 5.56 | Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation. ( Fatemi, I; Goudarzi, M; Hosseinzadeh, A; Karimi, MA; Khalili, HR; Khodayar, MJ; Mehrzadi, S, 2020) |
| "Nephrotoxicity is a significant side effect of doxorubicin (DXN) treatment." | 1.56 | Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation. ( Fatemi, I; Goudarzi, M; Hosseinzadeh, A; Karimi, MA; Khalili, HR; Khodayar, MJ; Mehrzadi, S, 2020) |
| " We also observed a joint effect of high statin dosage and renal disease (p = 0." | 1.34 | Risk factors for statin-associated rhabdomyolysis. ( Andrade, SE; Blough, D; Burgess, M; Chan, KA; Graham, D; La Grenade, L; Platt, R; Schech, S; Shatin, D; Staffa, J; Stergachis, A, 2007) |
| "Over the last three decades, hypolipemiants like fibric acid derivatives and statins have been increasingly recognised as causes of rhabdomyolysis and acute renal failure especially during combination therapy and in the presence of underlying renal impairment." | 1.31 | Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. ( Kamaliah, MD; Sanjay, LD, 2001) |
| "Gemfibrozil was determined in plasma and urine by means of a HPLC method." | 1.28 | Gemfibrozil absorption and elimination in kidney and liver disease. ( Knauf, H; Kölle, EU; Mutschler, E, 1990) |
| " Time to peak concentration (hr) was 2." | 1.27 | The effect of renal function on the pharmacokinetics of gemfibrozil. ( Cutler, RE; Evans, JR; Forland, SC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Thongnak, L | 1 |
| Pengrattanachot, N | 1 |
| Promsan, S | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Jaikumkao, K | 1 |
| Lungkaphin, A | 1 |
| Hosseinzadeh, A | 1 |
| Goudarzi, M | 1 |
| Fatemi, I | 1 |
| Khodayar, MJ | 1 |
| Mehrzadi, S | 1 |
| Khalili, HR | 1 |
| Karimi, MA | 1 |
| Schech, S | 1 |
| Graham, D | 1 |
| Staffa, J | 1 |
| Andrade, SE | 1 |
| La Grenade, L | 1 |
| Burgess, M | 1 |
| Blough, D | 1 |
| Stergachis, A | 1 |
| Chan, KA | 1 |
| Platt, R | 1 |
| Shatin, D | 1 |
| Guzik, TJ | 1 |
| Harrison, DG | 1 |
| Simsolo, RB | 1 |
| Ong, JM | 1 |
| Kern, PA | 1 |
| Broeders, N | 1 |
| Knoop, C | 1 |
| Antoine, M | 1 |
| Tielemans, C | 1 |
| Abramowicz, D | 1 |
| Lipscombe, J | 1 |
| Lewis, GF | 1 |
| Cattran, D | 1 |
| Bargman, JM | 1 |
| Tsimihodimos, V | 1 |
| Kakafika, A | 1 |
| Elisaf, M | 2 |
| Kamaliah, MD | 1 |
| Sanjay, LD | 1 |
| Bairaktari, E | 1 |
| Seferiadis, K | 1 |
| Liamis, G | 1 |
| Psihogios, N | 1 |
| Tsolas, O | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Knauf, H | 1 |
| Kölle, EU | 1 |
| Mutschler, E | 1 |
| Evans, JR | 1 |
| Forland, SC | 1 |
| Cutler, RE | 1 |
1 review available for gemfibrozil and Kidney Diseases
| Article | Year |
|---|---|
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
12 other studies available for gemfibrozil and Kidney Diseases
| Article | Year |
|---|---|
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki | 2023 |
Gemfibrozil attenuates doxorubicin induced toxicity in renal tissues of male rats by reducing the oxidative insult and inflammation.
Topics: Animals; Antibiotics, Antineoplastic; Cytochrome P-450 CYP2C8 Inhibitors; Doxorubicin; Gemfibrozil; | 2020 |
Risk factors for statin-associated rhabdomyolysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Drug Therapy, Combin | 2007 |
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil; | 2007 |
Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase.
Topics: Adipose Tissue; Adult; Diabetes Mellitus, Type 1; Electrophoresis, Polyacrylamide Gel; Gemfibrozil; | 1993 |
Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Topics: Bezafibrate; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidem | 2000 |
Deterioration in renal function associated with fibrate therapy.
Topics: Adult; Aged; Creatinine; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Ki | 2001 |
Fibrate treatment can increase serum creatinine levels.
Topics: Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Ki | 2001 |
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
Topics: Acute Kidney Injury; Aged; Bezafibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypo | 2001 |
Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine.
Topics: beta 2-Microglobulin; Biomarkers; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; K | 2002 |
Gemfibrozil absorption and elimination in kidney and liver disease.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Gemfibrozil; Half-Life; Humans; Intestina | 1990 |
The effect of renal function on the pharmacokinetics of gemfibrozil.
Topics: Aged; Gemfibrozil; Half-Life; Humans; Hypolipidemic Agents; Kidney Diseases; Male; Middle Aged; Pent | 1987 |